Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT04981717 |
| Consolidated Lead Sponsor | Regeneron Pharmaceuticals |
| Therapeutic Condition Cohort | Respiratory and Pulmonary |
| Clinical Trial Phase | Phase III |
| Overall Recruitment Status | TERMINATED |
| Registered Enrollment | 446 participants (ACTUAL) |
| Registered Start Date | 2021-07-30 |
| WhyStopped Classification | Lack of Efficacy / Futility |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Emory Winship Cancer Institute | Atlanta, GA | Open Hospital Dossier -> |
| Velocity Clinical Research (Meridian) | Meridian, ID | Open Hospital Dossier -> |
| Rush University Medical Center | Chicago, IL | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Regeneron Pharmaceuticals across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.